Royalty Pharma (RPRX) Cash from Financing Activities (2019 - 2025)
Historic Cash from Financing Activities for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to -$299.6 million.
- Royalty Pharma's Cash from Financing Activities fell 1613.87% to -$299.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.2 billion, marking a year-over-year decrease of 42839.25%. This contributed to the annual value of -$1.2 billion for FY2025, which is 42839.25% down from last year.
- Per Royalty Pharma's latest filing, its Cash from Financing Activities stood at -$299.6 million for Q4 2025, which was down 1613.87% from $562.7 million recorded in Q3 2025.
- Royalty Pharma's Cash from Financing Activities' 5-year high stood at $1.2 billion during Q2 2024, with a 5-year trough of -$1.4 billion in Q3 2023.
- Over the past 5 years, Royalty Pharma's median Cash from Financing Activities value was -$229.2 million (recorded in 2022), while the average stood at -$176.7 million.
- Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 49086.21% in 2023, then soared by 43332.11% in 2024.
- Over the past 5 years, Royalty Pharma's Cash from Financing Activities (Quarter) stood at -$198.1 million in 2021, then plummeted by 34.07% to -$265.6 million in 2022, then increased by 12.67% to -$231.9 million in 2023, then dropped by 11.24% to -$258.0 million in 2024, then dropped by 16.14% to -$299.6 million in 2025.
- Its Cash from Financing Activities stands at -$299.6 million for Q4 2025, versus $562.7 million for Q3 2025 and -$507.8 million for Q2 2025.